Company Overview PDF Print E-mail

Leader in First-in-Class Monoclonal Antibodies Focused on the Treatment and Diagnosis of Cancer


Our Mission

Delivering innovative and high quality biopharmaceutical products to improve patient lives


Our Values:

  • Passion: We have a deep personal drive to improve patients’ lives
  • Innovation: We continuously pursue novel solutions
  • Integrity: We strive to do the right thing every time and accept responsibility for our actions
  • Teamwork: We foster collaboration and work together to achieve goals
  • Adaptability: We readily change to meet new challenges


About Peregrine

Peregrine Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer.  We are pursuing multiple clinical programs with our lead product candidate, bavituximab. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and outside customers.

Bavituximab, in combination with other anti-cancer agents, has demonstrated promising signs of anti-tumor activity.  Bavituximab is an investigational immunotherapy designed to assist the body's immune system by targeting and modulating the activity of phosphatidylserine (PS), a highly immune-suppressive signaling molecule expressed broadly on the surface of tumor cells and tumor blood vessel cells. PS targeting antibodies are thought to affect the immunosuppressive environment that many tumors establish in order to proliferate and spread, while also fighting cancer by activating immune cells that target and fight cancer.  Peregrine is working with recognized oncology leaders, including AstraZeneca (AZ), Memorial Sloane Kettering Cancer Center (MSKCC), the National Comprehensive Cancer Network (NCCN) and the University of Texas Southwestern Medical Center to advance its research and clinical programs, and to capture the value that we believe exists in new bavituximab therapeutic combinations and indications.  For more information about bavituximab, click here. For more information on antibody mediated blockade of the phosphatidylserine (PS) signaling pathway, click here.

In addition to drug development, Peregrine’s wholly-owned subsidiary, Avid Bioservices, is a growing commercial biomanufacturing business that provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for Peregrine and other biotechnology and biopharmaceutical companies. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing utilizing stainless steel and single use technology, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit